Immunopharmacologic properties of WY-16, 922, a new orally effective antiallergic agent.
In a series of tests designed to illustrate immune reactions similar to those obtained in atopic disease, Wy-16,922 effectively inhibited reaginic-mediated immunologic reactions in the skin, lungs and mast cell. It was found to be devoid of immunosuppressant, antimediator, anti-inflammatory, steroid or bronchodilator properties as well as acute toxicity. Although the mechanism of action of Wy-16,922 is unknown, it appears to limit the release (not the effects) of allergic mediators in a manner similar to that described for disodium cromoglycate.
D000707:Anaphylaxis / Q000188:drug therapy; D000813:Anilides / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000494:pharmacology; D000937:Antigen-Antibody Reactions / Q000187:drug effects; D004205:Cromolyn Sodium / Q000494:pharmacology; D004285:Dogs; D006634:Histamine H1 Antagonists / Q000494:pharmacology* / Q000627:therapeutic use / Q000633:toxicity; D006636:Histamine Release / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000494:pharmacology; D008168:Lung / Q000378:metabolism; D008297:Male; D008407:Mast Cells / Q000378:metabolism; D051379:Mice; D010323:Passive Cutaneous Anaphylaxis / Q000187:drug effects; D051381:Rats
D000813:Anilides; D000893:Anti-Inflammatory Agents; D006634:Histamine H1 Antagonists; D007166:Immunosuppressive Agents; D004205:Cromolyn Sodium